Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer

Ren, Ning; Tian, Zhenmin; Sun, Hongmei; Lü, Xiaofei

doi:10.12659/msm.924590

Cited by 6 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression profiling of Dynamin 2 (an apoptotic protein) among 112 patients of PTC (Ren et al, 2020) revealed that recurrence and poor prognosis are positively associated with the expression of DNM 2. Therefore, DNM 2 expression may help in the screening of the patients at high risk for clinical therapy.…”

Section: Dynamin 2 and Programmed Death-ligand 1 (Pd-l1)mentioning

confidence: 99%

Unfolding of Imminent Bio-Signatures in the Prognosis of Thyroid Cancer; The Emergence of Estrogen Related Receptor Gamma (ERRγ) as a Hurricane

Gulwani

Upadhyay

Goel

et al. 2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Thyroid cancer's incidence has increased by leaps and bounds over the last years and accounts for 2.8% of new cases of cancers. This increasing bar is partially assisted by enormous screening to understand the sub-clinical status. Advanced tumor growth is the leading cause of thyroid cancer-associated death. However, the complete understanding of the underlying cause is still to be disclosed. The updated clinical assessment evidenced a few major oncogenes viz. RAS, BRAF, and RET as key drivers in the development and progression of thyroid cancer. The BRAF mutation, a major cause of aggressive tumor type in papillary thyroid carcinoma, is frequently reported. The characteristic oncogenic changes imply thyroid cancer to be clinically an ideal model for targeted therapy against RET, RAS, and BRAF mutation. Though the sensitive biochemical marker assay has been improvised, the diagnosis of thyroid follicular neoplasms is still a big challenge as the biopsy aspiration cannot define the nature of the tumor in 30% of the cases. The main hurdle is assisted distinction between follicular thyroid lesions. The discrimination between follicular thyroid adenomas and carcinomas is histologically accomplished. This strictly necessitates the identification of sensitive diagnostic/prognostic markers to mitigate the risk of thyroid cancer and to avoid the unnecessary hurdles of biopsy and surgery. An array of prognostic biomarkers is being used for the diagnosis of thyroid cancer. However, Estrogen Related Receptor Gamma (ERRγ) is setting a new benchmark among the clinical biomarkers. The dramatic expression of ERRγ in thyroid cancer enables itself not only to serve as a characteristic diagnostic marker but also as a therapeutic target. Recently, we have reported that ERRγ is upregulated in 96 papillary thyroid cancer (PTC) and 26 poorly differentiated/ anaplastic thyroid cancer (ATC) samples. Various synthetic ERRγ inverse agonists viz. GSK5182, DN200434, and 24e are fully proved to modulate ERRγ expression in ATC to attain partial cure. If this finding can be assayed on a larger scale the evaluation of this marker may be warranted and informative. This review article highlights the ascending sheds of clinical biomarkers of thyroid cancer. This also reveals the clinical importance of ERRγ as an evolving diagnostic and therapeutic target in thyroid cancer.

show abstract

Section: Dynamin 2 and Programmed Death-ligand 1 (Pd-l1)mentioning

confidence: 99%

Unfolding of Imminent Bio-Signatures in the Prognosis of Thyroid Cancer; The Emergence of Estrogen Related Receptor Gamma (ERRγ) as a Hurricane

Gulwani

Upadhyay

Goel

et al. 2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…DNM2 overexpression was also demonstrated in stem cells and progenitor cells of chronic myeloid leukemia (CML), i.e. a clonal myeloproliferative disorder originating from hematopoietic stem cells [32], in multiple ovarian cancer data sets [33], in bladder tumors in which the overexpression is correlated with the grade progression [34], in papillary thyroid cancer in which high DNM2 expression is associated with unfavourable prognosis (tumor recurrence, overall survival rate, distant metastases) [35], and in prostate cancer in which high DNM2 expression is associated with higher aggressiveness (Gleason score) and mortality [36,37]. DNM2 overexpression was also reported in cervical cancer.…”

Section: Dnm2 Deregulation In Cancersmentioning

confidence: 99%

A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target

Trochet

Bitoun

2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Dynamin 2 (DNM2) is an ubiquitously expressed large GTPase well known for its role in vesicle formation in endocytosis and intracellular membrane trafficking also acting as a regulator of cytoskeletons. During the last two decades, DNM2 involvement, through mutations or overexpression, emerged in an increasing number of cancers and often associated with poor prognosis. A wide panel of DNM2-dependent processes was described in cancer cells which explains DNM2 contribution to cancer pathomechanisms. First, DNM2 dysfunction may promote cell migration, invasion and metastasis. Second, DNM2 acts on intracellular signaling pathways fostering tumor cell proliferation and survival. Relative to these roles, DNM2 was demonstrated as a therapeutic target able to reduce cell proliferation, induce apoptosis, and reduce the invasive phenotype in a wide range of cancer cells in vitro. Moreover, proofs of concept of therapy by modulation of DNM2 expression was also achieved in vivo in several animal models. Consequently, DNM2 appears as a promising molecular target for the development of anti-invasive agents and the already provided proofs of concept in animal models represent an important step of preclinical development.

show abstract

“…2,3 AD-CNM results from mutations in the DNM2 gene (OMIM: *602378, which encodes dynamin 2 (DNM2). 4 In addition, DNM2 mutations also cause rare forms of Charcot-Marie-Tooth disease (CMT, OMIM: #606482) 5 and hereditary spastic paraplegia (HSP), 6 and a deleterious DNM2 overexpression was reported in several cancers [7][8][9][10][11][12] and the X-linked recessive CNM, 13 highlighting a large DNM2 involvement in human diseases. DNM2 belongs to the superfamily of large GTPases 14 acting as a mechanochemical scaffolding molecule that oligomerizes and deforms biological membranes leading to the formation and release of vesicles from the plasma membrane and intracellular membrane compartments.…”

Section: Introductionmentioning

confidence: 99%

Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations

Dudhal

Mekzine

Prudhon

et al. 2022

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer

Cited by 6 publications

References 31 publications

Unfolding of Imminent Bio-Signatures in the Prognosis of Thyroid Cancer; The Emergence of Estrogen Related Receptor Gamma (ERRγ) as a Hurricane

Unfolding of Imminent Bio-Signatures in the Prognosis of Thyroid Cancer; The Emergence of Estrogen Related Receptor Gamma (ERRγ) as a Hurricane

A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target

Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations

Contact Info

Product

Resources

About